Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
This recognition demonstrate excellence in intellectual property (IP) value creation.
The move strengthens GBL’s clinical-stage presence in the United States
Patients with BRCA mutations often face aggressive disease and poor prognosis
India plays a critical role in Bristol Myers Squibb’s global strategy
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
Subscribe To Our Newsletter & Stay Updated
